Curious about today's AI digest?ai-tldr.dev

Daily Digest

Summit Therapeutics Falls as FDA Rejects Lung Cancer Drug

HealthcareMAJOR20m ago4 min read
Share
Summit Therapeutics Falls as FDA Rejects Lung Cancer Drug

Summit Therapeutics (SMMT) slid in premarket trading after the FDA rejected ivonescimab, its Akeso-partnered lung cancer drug, over missing survival data.

  • Summit fell about 12% premarket Monday, later extending losses to 17% near $11.70, after the FDA declined to approve ivonescimab.
  • The FDA said a progression-free survival gain without statistically significant overall survival does not establish effectiveness.
  • Akeso's Hong Kong shares closed down 22% as the setback hit the PD-1/VEGF drug class.

Lead

Summit Therapeutics (NASDAQ: SMMT) fell about 12% in premarket trading on Monday, November 16, after the US Food and Drug Administration issued a complete response letter for ivonescimab. The agency declined to approve the drug in combination with platinum chemotherapy for adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) that has progressed after treatment with an EGFR-targeted therapy. Losses widened as the session approached, with the stock trading near $11.70, down about 17% from Friday's close of $14.15 and below its prior 52-week low of $12.07. The decision arrived a day after the November 14 target date. For investors in biotech cancer stocks, it is a pointed reminder of how heavily regulators now weigh survival evidence.

What Did the FDA Say About Ivonescimab?

The FDA said substantial evidence of effectiveness was not established because the pivotal HARMONi trial did not show a statistically significant improvement in overall survival. In the letter, the agency concluded that a progression-free survival benefit, absent a significant survival gain, does not support a positive benefit-risk profile.

The trial met its primary progression-free survival goal, with a hazard ratio of 0.52 and median survival without progression of 6.8 months versus 4.4 months for chemotherapy alone. Overall survival favored ivonescimab, at 16.8 months versus 14.0 months, but the 0.79 hazard ratio carried a p-value of 0.057, short of the 0.05 threshold. A later data cut showed a hazard ratio of 0.76. The FDA did not accept that post-hoc analysis, which drew on a larger share of non-Asian patients.

Why Did Akeso and the Wider Class Sell Off?

Akeso (HKEX: 9926), which discovered ivonescimab and licensed most global rights to Summit in 2022, fell as much as 32% in Hong Kong on Monday and closed down 22% at HK$64.10. The drug is the most advanced of a group of PD-1/VEGF bispecific antibodies that have drawn heavy investment since its first positive data in 2024. A US rejection at the first regulatory test removes the earliest route to market for the class and signals that the FDA will hold such agents to a survival standard.

What Does This Mean for Summit's Pipeline?

The letter leaves Summit without an approved product. The company reported cash of $629.8 million at the end of the third quarter and has not announced a plan to resubmit for this indication. The BLA had been accepted on January 29, 2026.

Attention shifts to HARMONi-3, a global first-line NSCLC study comparing ivonescimab plus chemotherapy with Merck's (MRK) Keytruda plus chemotherapy. A progression analysis in the squamous cohort and an early survival look are expected in the fourth quarter of 2026. Further survival and non-squamous data are slated for the first half of 2027. Those readouts will test the drug in a larger population where overall survival is the central endpoint.

Outlook

The rejection delays US commercialization of ivonescimab and puts a spotlight on survival endpoints for the whole PD-1/VEGF class. The company's next catalyst is the HARMONi-3 squamous readout expected by year-end. Results there are likely to set the stock's direction, and Akeso's, more than the lung cancer rejection itself.

Mentioned tickers: SMMT, 9926.HK, MRK

The Daily Briefing

Every story that moved the market, every weekday.

Market news - the major stories only, free, and one email a day.

One email a day. Unsubscribe anytime.